Gary L. Goldberg

Dr. Gary L. Goldberg

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
RSRisha Sinha
Risha Sinha
BBBethany Bustamante
Bethany Bustamante
FTFarnaz Tahmasebi
Farnaz Tahmasebi
GGGary L. Goldberg
Gary L. Goldberg
• Of the fewer than 100 FATWO case reports published, at least 25 reports have metastatic quality. • Very little information regarding optimal management of FATWO is known; immunohistochemical stains may help guide therapy. • FATWO may be more of a low malignant potential entity, and patients with the diagnosis should be followed closely.

1 May 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
RSRisha Sinha
Risha Sinha
BBBethany Bustamante
Bethany Bustamante
ATAlexander Truskinovsky
Alexander Truskinovsky
GGGary L. Goldberg
Gary L. Goldberg
KSKarin K. Shih
Karin K. Shih
• Seven of eighteen postmenopausal female endometrial YST cases were pure YST. • IHC supports somatic tumor cell retro-differentiation yielding extra-gonadal YST. • Studying genetic alterations in endometrial YST may elucidate its histiogenesis.

16 September 2009 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
MHMehrangiz Hatami
Mehrangiz Hatami
KWKathleen Whitney
Kathleen Whitney
GGGary L. Goldberg
Gary L. Goldberg

22 November 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
ANAaron Nizam
Aaron Nizam
BBBethany Bustamante
Bethany Bustamante
WSWeiwei Shan
Weiwei Shan
KSKarin K. Shih
Karin K. Shih
JWJill S. Whyte
Jill S. Whyte
GGGary L. Goldberg
Gary L. Goldberg
Background: Carcinosarcoma of the ovary (CSO) is a rare and aggressive variant of ovarian cancer. Due to the rare nature of the disease there is insufficient evidence to make recommendations regarding standard management and overall prognosis. Methods: An Institutional Review Board-approved study identified all our patients with CSO between January 2011 and May 2018. Demographic and outcome measures were abstracted from the medical records and tumor board files. Cox proportional hazard models, log rank tests, and comparisons of means were used to calculate significance (p < 0.05). Results: 27 women with CSO were identified. The median age at diagnosis was 65 years (range 48–91). Five women (18%) presented with early stage disease (Stage I or II) and 22 patients (82%) presented with late stage III or IV disease. Twenty patients (74%) received intravenous platinum-based combination chemotherapy. Seven patients did not receive chemotherapy during their treatment course. The median overall survival was 23 months (range 2–68 months). Overall survival was not significantly worsened by the stage of disease at diagnosis. There was no difference in survival based on the age at diagnosis, tobacco status or ethnicity (p > 0.05). Conclusion: This is one of the largest single institution experiences with CSO. The majority of our patients presented with advanced stage disease and received adjuvant platinum-based chemotherapy after cytoreductive surgery. The median overall survival of 23 months was not affected by the stage of the disease. The optimal management of this rare disease needs further study with collaborative, prospective multi-institutional trials.

21 July 2022 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
KSKieran Seay
Kieran Seay
BBBethany Bustamante
Bethany Bustamante
ATAlexander Truskinovsky
Alexander Truskinovsky
AMAndrew Menzin
Andrew Menzin
GGGary L. Goldberg
Gary L. Goldberg
Intestinal type mucinous adenocarcinoma (iMACE) is a rare and unusual variant of mucinous carcinoma of the endometrium that can show focal features of poorly differentiated adenocarcinomas of gastric, pancreatic or intestinal origin by producing signet ring cells. To date, only two reported cases of signet ring cells as a morphological feature of iMACE have been reported. Alterations in E-cadherin expression have been linked to increased metastatic potential, tumor dedifferentiation, and deep myometrial invasion in endometrial carcinomas. The presence or absence of E-cadherin in iMACE with signet-ring cells has not been studied. Thus, we sought to analyze E-cadherin expression in this aggressive variant of endometrial carcinoma. Diagnosis of iMACE with signet ring cells was rendered with the aid of immunohistochemical staining and histological analysis. Average age of diagnosis was 72 with the presenting complaint of postmenopausal bleeding in all three women. Focal loss or weakly positive E-cadherin expression was seen in areas of signet-rings cell morphology in all three cases. This case report adds to the body of literature that demonstrates the aggressive nature of intestinal differentiation in the endometrium. In addition, this report suggests that the presence of signet-rings cells and loss of E-cadherin expression may render a poorer prognosis as seen in other parts of the body.

18 February 1991 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
GGGary L. Goldberg
Gary L. Goldberg
MAM.M. Altaras
M.M. Altaras
BBB. Bloon
B. Bloon